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Abstract
Objective—Interleukin-2 receptor subunit alpha (IL-2Rα) regulates lymphocyte activation, 
which plays an important role in atherosclerosis. Associations between soluble IL-2Rα and 
cardiovascular disease (CVD) have not been widely studied and little is known about the genetic 
determinants of sIL-2Rα levels.
Approach and Results—We measured baseline levels of sIL- 2Rα in 4408 European-
American (EA) and 766 African-American (AA) adults from the Cardiovascular Health Study 
(CHS) and examined associations with baseline CVD risk factors, subclinical CVD and incident 
CVD events. We also performed a genome-wide association study (GWAS) for sIL-2Rα in CHS 
(2964 EAs and 683 AAs) and further combined CHS EA results with those from two other EA 
cohorts in a meta-analysis (N=4464 EAs). In age, sex- and race- adjusted models, sIL-2Rα was 
positively associated with current smoking, type 2 diabetes, hypertension, insulin, waist 
circumference, C-reactive protein, interleukin-6, fibrinogen, internal carotid wall thickness, all-
cause mortality, CVD mortality, and incident CVD, stroke and heart failure. When adjusted for 
baseline CVD risk factors and subclinical CVD, associations with all- cause mortality, CVD 
mortality and heart failure remained significant in both EAs and AAs. In the EA GWAS analysis, 
we observed 52 single nucleotide polymorphisms (SNPs) in the chromosome 10p15-14 region, 
which contains IL2RA, IL15RA and RMB17, that reached genome-wide significance (p<5×10-8). 
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The most significant SNP was rs7911500 (p=1.31×10-75). The EA meta-analysis results were 
highly consistent with CHS-only results. No SNPs reached statistical significance in the AAs.
Conclusions—These results support a role for sIL-2Rα in atherosclerosis and provide evidence 
for multiple associated SNPs at chromosome 10p15-14.
Keywords
IL-2Ra; Inflammation; Atherosclerosis; Genome-wide association
Introduction
Interleukin (IL)-2 and IL-2 receptor (IL-2R) signaling play an important role in regulating 
both tolerance and immunity. IL-2 is a T cell growth factor, inducing the proliferation and 
differentiation of antigen-activated T cells1,2, and is particularly important in the 
development of regulatory T cells in the thymus3. The IL-2R is a trimeric receptor composed 
of the IL-2Rα subunit (CD25), the IL-2Rβ subunit (CD122), and the IL-2γc subunit 
(CD132). IL-2Rα is specific for IL-2R, while IL-2Rβ and IL-2Rγc are shared components 
of other cytokine receptors (e.g., IL-15)4,5. sIL-2Rα results from the proteolytic cleavage of 
IL-2Rα at the cell surface by a membrane metalloproteinase (ectodomain shedding)6; which 
is encoded by IL2RA on human chromosome 10. The function of sIL-2Rα has not been 
fully elucidated. Since the sIL-2Rα has IL-2 binding kinetics similar to the membrane form, 
sIL-2Rα may serve to mitigate the immune responses by binding and sequestering IL-27.
High plasma levels of sIL-2Rα have been associated with autoimmune diseases including 
Crohn's disease8, rheumatoid arthritis9, and multiple sclerosis10 and higher levels have been 
observed in patients with coronary artery disease11. Murine models have shown that IL-2 
increases regulatory T cell numbers in atherosclerotic plaques and also reduces the size of 
those plaques12. When the IL-2 receptor is blocked in the same model, the plaque reduction 
is negated.
Despite its potential importance in the immune system and cardiovascular disease (CVD), 
sIL-2Rα has not been widely investigated in large prospective population-based studies of 
CVD. A 2003 study in the Health, Aging and Body Composition (Health ABC) study did 
not result in evidence for a significant association between sIL-2Rα and CVD; however, 
sIL-2Rα measurements were only available in a subset of N=499 participants. In addition, 
little is known about the genetic determinants for sIL-2Rα levels. While genome-wide 
association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the 
IL-2RA gene for several autoimmune diseases10, there have been no published reports for 
GWAS of serum levels of sIL- 2Rα.
In the current study, we examined sIL-2Rα levels in the Cardiovascular Health Study (CHS), 
a cohort of older adults with follow-up for incident clinical CVD and mortality for up to 20 
years. We examined the relationships between sIL-2Rα at baseline and incident events as 
well as cross-sectionally with other CVD and inflammatory markers (fibrinogen, C-reactive 
protein [CRP], and IL-6). We then conducted a GWAS and region-specific conditional 
analyses to identify genetic variants associated with sIL-2Rα levels. Finally, we performed a 
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GWAS meta- analysis, including results from two additional studies: the Health ABC study 
and the Multi- Ethnic Study of Atherosclerosis (MESA), to increase our power to detect 
associated variants not detected in CHS alone.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Associations between sIL2Rα and baseline CVD risk factors and other inflammation 
biomarkers
The characteristics of the 5174 CHS participants with sIL-2Rα measurements at the baseline 
exam are summarized in Table 1, and Spearman correlation coefficients for sIL-2Ra with 
each continuous CVD risk factor and IMT are given in Supplemental Table I. sIL-2Rα levels 
were on average higher in older individuals, higher in men, and higher in EAs. At baseline, 
mean sIL-2Rα levels were 1146.4 pg/mL (standard deviation (SD)=507.5 pg/mL) and 
1101.6 pg/mL (SD=556.4 pg/mL) in EA men and women, respectively; and 873.1 pg/mL 
(SD=505.5 pg/mL) and 910.9 pg/mL (SD=581.2 pg/mL) in AA men and women, 
respectively. In age-, race- and sex-adjusted models sIL-2Rα was additionally associated 
with current smoking, type 2 diabetes, hypertension, fasting insulin, waist circumference, 
CRP, IL-6, fibrinogen, and internal carotid wall IMT and negatively associated with LDL 
and high density lipoprotein (HDL) cholesterol. After further adjustment, sIL2Ra levels 
remained associated with age, race, smoking, hypertension, lipids, and inflammation.
Incident events analysis
We performed survival analysis in 4406 EAs and 768 AAs. There were 2985(EA)/451(AA) 
all- cause deaths; including 1202/186 cases of cardiovascular mortality. There were 
1234/195 incident cases of CHD, 762/117 incident strokes, and 1246/199 incident cases of 
heart failure (fatal and non-fatal events). When minimally adjusted for age, sex, race, and 
study site, baseline sIL-2Rα was significantly associated with increased risk for all 
outcomes in both EAs and AAs (Table 2). Results were slight attenuated in EAs after 
additional adjustment for baseline risk factors except for stroke, and not attenuated at all in 
AAs. When further adjustment was made for inflammation status and measures of 
subclinical CVD, all-cause mortality and heart failure remained significant for both the EAs 
and AAs; cardiovascular mortality remained significant only for EAs; and stroke remained 
significant only for AAs. Effect estimates were mostly similar between EAs and AAs 
(sIL-2Rα as a continuous predictor). In analyses where sIL-2Rα was modeled in quartiles, 
the risk of increased sIL-2Rα for stroke in AAs appears to be driven by the highest quartile 
of sIL-2Rα as compared to a more graded effect in EAs. We estimated a 63%(EA)/67%
(AA) increased risk for all-cause mortality, and a 57%/71% increased risk of heart failure for 
individuals in the fourth quartile versus those in the first quartile, after adjustment for both 
established CVD risk factors, inflammation biomarkers and subclinical measures of CVD. 
For cardiovascular mortality, this estimated increased risk was 64% in EAs and not 
significant in AAs; and 28% in EAs and 130% in AAs for stroke.
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Genome-wide association study of sIL-2Rα in CHS EA and AA
We conducted a race-stratified GWAS in 2964 EAs and 683 AAs from CHS that had both 
sIL- 2Rα measurement and GWAS data available. A total of 52 SNPs in the chromosome 
10p15- p14 region (containing IL2RA, IL15RA, and RBM17) reached genomewide 
significance (p<5×10-8) in the EA analysis. The most significant SNP was rs7911500 
(p=1.31×10-75), which is located between IL2RA and IL15RA. No other regions reached 
genome-wide significance in the EA analysis. No SNPs reached genome-wide significance 
in the AA analysis. The top findings in AAs were for an intergenic SNP between BRE and 
FOSL2 on chromosome 2 (rs7602568, p=5.8×10-6) and an intronic SNP in ADK 
(rs12220238, p=8.3×10-6), nearly 70Mb from IL2RA on chromosome 10. IL2RA SNP 
rs7911500 (p=0.52) demonstrated no evidence for association in AAs, though the minor 
allele frequency for this variant in AAs was only 2.5% (compared to 13.4% in EAs). Several 
chromosome 10p15-p14 SNPs between IL15RA and IL2RA (lead SNP rs8177607, 
p=3.2×10-4) provided nominal evidence for an association in AAs. rs8177607 showed no 
evidence for association in EAs (p=0.65).
Conditional and multiple variant analysis of IL2RA region in CHS EA
In the CHS EAs, as described in Methods, we performed an iterative, forward-selection 
conditional analysis of the chromosome 10p14-15 region (approximately a 200 Kb span), 
beginning with conditioning on the rs7911500 SNP (Figure 1). The order of additional SNP 
conditioning was rs791590 (pcond=7.0×10-35; an intronic SNP in IL2RA), rs8177757 
(pcond=2.3×10-10; located between IL15RA and IL2RA), rs10905716 (pcond=3.3×10-9; 
located between IL2RA and RBM17), and finally rs7924005 (pcond=4.4×10-10; located in 
LOC101928080 downstream from RBM17). There was still nominal evidence for further 
association of SNPs in the region after adjusting for these five, although none reached 
genome-wide significance. The multiple variant penalized regression method LLARRMA 
identified six SNPs (Resample Model Inclusion Probability (RMIP) > 0.8; namely, 
rs2104286 (RMIP =1.00), rs7924005 (RMIP=0.995), rs10905716 (RMIP=0.995), rs4749955 
(RMIP=0.911), rs11256497 (RMIP=0.899), and rs7898880 (RMIP=0.871)) that were 
consistently associated with sIL-2Rα levels across alternative resamplings of the data. Our 
top SNP in our initial GWAS, rs7911500 (RMIP = 0.002) was not predicted to be important 
in the multi-SNP LLARRMA model. However, LLARRMA did include the top variant, 
rs791590 (RMIP = 0.592), from the conditional analysis after conditioning on rs7911500, 
more often than not in the final multi-SNP model across different resamplings of the data.
The five index SNPs identified in the conditional analysis, in total explain approximately 
14% of the variation in sIL-2Rα levels after adjusting for age, sex and PCs to account for 
population admixture. When we further examined these five SNPs individually for 
association with incident cardiovascular events in CHS, none of them was significant. We 
also observed no evidence for an association between a genetic risk score (equal to the sum 
of the alleles individually associated with increased sIL-2Rα for these five SNPs) and 
clinical events.
Durda et al. Page 5













Meta-analysis of CHS, MESA and Health ABC EA
We conducted a meta-analysis combining GWAS results for CHS (N=2964), MESA 
(N=714) and Health ABC (N=786) EA participants to increase power to detect loci 
potentially missed in the CHS-only analysis. Meta-analysis results were highly consistent 
with those observed in the CHS-only analysis, where only variants in the chromosome 
10p15-p14 region (IL15RA/IL2RA/RBM17) reached statistical significance (Figure 2). A 
total of 95 SNPs in this region were significant in the meta-analysis, and the most significant 
SNP remained rs7911500 (p = 1.1 ×10-100).
We assessed the evidence for association between sIL2r and 1093 variants reported as 
significant in prior GWAS studies, according to the NHGRI GWAS catalogue (https://
www.genome.gov) for the traits listed in Table 1. Only our top two SNPs, rs7911500 and 
rs12722606, which were previously reported to be significantly associated with an 
inflammatory phenotype based on the IL-6 – CRP pattern, were statistically significant with 
the sIL2rα levels in this candidate variant analysis after Bonferroni correction for 1093 test 
(p<4.6×10-5). Additionally, we searched the CARDIoGRAM+C4D database containing data 
from multiple GWAS (63,746 case and 13,0681 controls) combined to determine variants 
associated with coronary artery disease and myocardial infarction (http://
www.cardiogramplusc4d.org14,15,16). No significant associations (all p>0.05) between our 
SNPs and CVD were identified.
Discussion
We report the first large-scale assessment of sIL-2Rα for association with CVD related traits 
and events in a prospective cohort and the first GWAS for SNPs associated with sIL-2Rα 
levels. The major findings from this study are: A) sIL-2Rα levels are associated with a 
number of established CVD risk factors and carotid IMT, a measure of subclinical CVD. B) 
Plasma sIL- 2Rα predicted all-cause mortality and cardiovascular mortality independently 
of CVD risk factors and baseline subclinical CVD. C) In CHS alone (N=2961) we identified 
52 SNPs in the chromosome 10p15-p14 region with genome-wide significance for 
association with plasma sIL- 2Rα levels; most significant was rs7911500, intergenic to 
IL15RA and IL2RA. D) Conditional analysis indicated that there are multiple SNPs 
independently associated in this region; the five most significant loci, in total explain 
approximately 14% of the variation in plasma sIL- 2Rα levels in CHS EAs. E) Combining 
results from EAs in CHS and two additional cohort studies, MESA and Health ABC 
(n=4464), did not result in any additional significantly associated loci. F) We did not identify 
any significant associations in the CHS AAs, although we did observe nominal evidence for 
association in the IL15RA/IL2RA region. G) There was no evidence that sIL-2Rα-
associated SNPs were associated with incident clinical events in CHS; we also observed no 
evidence of association with coronary artery disease and myocardial infarction in a search of 
the CARDIoGRAM+C4D database results for these SNPs14,15,16
Activated T lymphocytes play an important role in atherosclerosis promoting chemokine 
secretion, inflammation, and eventually, the formation of atherosclerotic plaques. IL-2, 
produced by T helper 1 cells, has been found in plaques and contributes to the development 
of atherosclerosis by its interaction with the IL-2 receptor increasing lymphocyte 
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activation13. IL-2 stimulates the synthesis of interferon gamma thereby promoting an 
increased immune response and atherosclerotic progression. However, IL-2 also promotes 
regulatory T cells, and may have an atheroprotective role as well12.
While sIL-2Rα is a strong biological candidate for use as a biomarker for CVD morbidity 
and mortality, epidemiologic studies have been limited. Analysis in the Health ABC study 
did not identify evidence for an association between sIL-2Rα and either subclinical (p=0.27) 
or clinical CVD (p=0.27), but measured sIL-2Rα levels were only available on a subset of 
499 of the 3045 participants with incident event data. Although it was not statistically 
significant, median sIL-2Rα level was slightly higher in those with incident clinical CVD as 
compared to those with no CVD (1.4 mg/mL versus 1.2 mg/mL)14. Investigators from 
another study of 286 Japanese patients that underwent angiography (167 coronary artery 
disease [CAD] cases and 119 controls) reported a significant positive association of sIL-2Rα 
and cross-sectional CAD case status based on extreme quartiles of sIL-2Rα (p=0.005 for 
minimally adjusted model and p=0.035 for model with additional adjustment for CVD risk 
factors)11. The current study represents the first well- powered effort examining sIL-2Rα 
level prospectively with clinical CVD events and all-cause mortality. We observed 
statistically significant evidence for all incident events examined (all- cause mortality, CVD 
mortality, incident CHD, stroke and heart failure) in minimally adjusted models, and for all-
cause mortality, CVD mortality and incident heart failure in fully adjusted models. We found 
sIL-2Rα levels to be significantly associated with carotid intima-media thickness in the 
minimally adjusted model; although this did not remain significant when other 
cardiovascular risk factors were added to the model.
Fifty-two chromosome 10p15-p14 SNPs were significantly associated (p<5×10-8) with 
plasma sIL-2Rα levels in CHS EAs; no other regions reached genome-wide significance. 
The most significant SNP, rs7911500, was located between IL15RA and IL2RA. Iterative 
conditional analyses identified a total of five significant “independent” SNPs across the 
region. LLARRMA identified six SNPs that were consistently associated with sIL-2Rα 
levels across alternative resamplings of the data. Both iterative conditional analyses and 
LLARRMA provide compelling evidence for the existence of multiple important causal 
variants in the region, though they did not agree with respect to the importance of our most 
significant SNP, rs7911500. Higher density genotype data, including both common 
haplotype-tagging variants and less-common putative functional variants, will be necessary 
to fine map the association signals in this region. Two of our significant SNPs in the region, 
rs2104286 (p=4.9×10-59; the top SNP identified by LLARRMA) and rs11594656 
(p=1.5×10-41), have been shown to function in transcription factor binding. These SNPs 
have also been reported to be associated with sIL2Rα levels and type 1 diabetes and 
multiple sclerosis15, 16.
No regions reached genome-wide significance in the smaller cohort of CHS AAs. Nominal 
evidence for association in AAs was detected between IL15RA and IL2RA (best result: 
rs8177607, p=3.2×10-4). The lead SNP in EAs, rs7911500, was less polymorphic in AAs 
and demonstrated no evidence for association. Similarly, no evidence for association was 
found for rs791590 (p=0.31) or rs10905716 (p=0.43), two significant variants in EAs in the 
conditional analyses. The two other significant SNPs in the conditional analyses, rs8177757 
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and rs7924005, were not successfully imputed in the AAs. The difference in findings 
between EAs and AAs could suggest different risk variants in the two populations, be 
reflective of different LD structures in the region that mask common underlying causal 
variants, or be the result of lower power in AAs. There are strong allele frequency 
differences between the two populations for many of the EA SNPs in the region (see 
Supplemental Table II for frequencies in HapMap CEU and YRI populations) and the AA 
sample size is considerably smaller than for EAs.
Interestingly, the top SNP from LLARRMA, rs2104286, in EAs was nominally significant 
in AAs (p=0.011) despite the lower estimated frequency of the minor allele in AAs 
(MAF=0.065) compared to EAs (MAF=0.27). The effect estimates for the SNP were similar 
in AAs (β = -0.17) and EAs (β =-0.15), where carriers of the minor allele were predicted to 
have lower sIL-2Rα levels.
Elevated sIL-2Rα levels have been shown to be associated with a number of autoimmune 
diseases and may predict a relapse of those diseases7. We found a number of IL2RA SNPs 
previously associated with autoimmune-related diseases to be significantly associated with 
sIL-2Rα levels. A number of our significant SNPs have also been observed to be associated 
in GWAS, fine mapping studies and SNP specific genotyping studies for autoimmune 
diseases including Graves' disease (rs11594656, Odds Ratio (OR)=1.54, p=0.0053)17, 
vitiligo (rs706779 OR=1.27, p=3×10-9)18, Crohn's disease (rs12722489, OR=1.11, 
p=3×10-9) 19, type 1 diabetes (rs7090530, OR=1.23, p=0.003)20 and multiple sclerosis 
(rs2104286, OR=0.81, p=0.017)20. Our two most significant SNPs, rs7911500 and 
rs12722605, were found to be significantly associated with an inflammatory phenotype 
derived from the high-sensitivity CRP-interleukin-6 (IL-6) pattern in a G W A S o f the 
Genetics of Lipid Lowering Drugs and Diet Network (p=5×10-9 and p=5×10-8)21. The 
nature of this association is uncertain; it is possible that these variants or others in linkage 
disequilibrium with them are directly increasing the sIL-2Rα levels which in turn results in 
downstream increases in both IL-6 and CRP.
There are several limitations in the current study which should be noted. We only analyzed 
common variants; rare polymorphisms may account for much of the variability in the 
sIL-2Rα levels. Also, we had weak statistical power to detect associations in AAs. Finally, 
our study was focused on older adults and the results may not be generalizable to other 
populations.
Our findings suggest that serum sIL-2Rα, a surrogate marker of T lymphocyte activation, 
may be a valuable novel biomarker for all-cause mortality, cardiovascular morality, stroke 
and heart failure in older adults. Additional studies are needed to assess whether sIL-2Rα 
levels predict mortality in younger populations. Also, further studies are needed a) to 
identify the causal variants in the chromosomal region harboring IL15RA and IL2RA 
influencing sIL-2rα, b) to provide very large and multi-ethnic samples to identify additional 
genetic loci for this trait, and c) to determine the complex biology of the genetic control of 
IL-2/IL-2R interactions with respect to regulatory T cell promotion and pro-inflammatory 
cytokine production.
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This study found that sIL-2Rα, a regulator of white blood cells, is associated with a 
number of cardiovascular disease risk factors, as well as with all-cause mortality, 
cardiovascular disease mortality, and heart failure in the Cardiovascular Health Study. 
Analysis of genetic variants in European Americans found a number of variants in the 
chromosome 10 region containing the genes IL2RA, IL15RA, and RMB17 to be 
significantly associated with sIL-2Rα. These results provide support for a role of 
sIL-2Rα in atherosclerosis and cardiovascular disease.
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Conditional analysis: A, Cardiovascular Health Study (CHS) interleukin (IL)2sR α adjusted 
by rs7911500. B, CHS IL2sR α adjusted by rs7911500 and rs791590. C, CHS IL2sR α 
adjusted by rs7911500, rs791590, and rs8177757. D, CHS IL2sR α adjusted by rs7911500, 
rs791590, rs8177757, and rs10905716. E, CHS IL2sR α adjusted by rs7911500, rs791590, 
rs8177757, rs10905716, and rs7924005.
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Meta analysis of European Americans.
Durda et al. Page 16

























Durda et al. Page 17
Table 1
Associations Between slL-2Rα and Other Cardiovascular Risk Factors and 
Atherosclerosis at the CHS Baseline Examination
Baseline Characteristics (Mean±SD or %) Model A, β±SE Model B, β±SE Model C, β±SE
Age, y (5.6) 0.074±0.005*** 0.078+0.006*** 0.067±0.006***
Female sex (57.2%) –0.029±0.011* –0.031±0.011* 0,017±0012
Black race (14.8%) –0.120±0.007*** –0.133±0.008*** –0.134±0.008***
Current smokIng (54.0%) 0.100±0.164*** 0.108±0017*** 0.079±0.017***
Type 2 diabetes mellitus (16.2%) 0.056±0.014** 0.042±0.015** –0.002±0.015
Hypertension (44.5%) 0.Q42±0.006*** 0.046±0.007*** 0.030±0.007***
Systolic blood pressure, mm Hg (136.6±21.8) 0.013±0.005 –0.011±0.026 0.003±0.007
LDL cholesterol, mg/dL (129.8±35.6) –0.030±0.005*** –0.030±0.005*** –0.032±0.007***
HDL cholesterol, mg/dL (54.2±15.7) –0.055±0.006*** –0.050+.0.006*** –0.046±0.006***
Triglycerides, mg/dL (139.8±76.7) 0.007±0.005 –0.002±0.006 –0.025±0.008*
Glucose, mg/dL (111.1 ±35.9) 0.013+0.005 –0.009±0.008 –0.013±0.007
Insulin, IU/mL(17.4±27.4) 0.023±0.005*** 0,017±0.005* 0.011±0.005
BMI. kg/m2(26.6±4.7) 0.009±0.006 0.005±0.006 –0.016±0.006*
waist circumference, cm (94.4±13.1) 0.014±0.005* 0.016±0.010 0.003±0.010
C-reactive protein, mg/L (4.8±8.0) 0.083±0.005** 0.080±0.005*** 0.043±0.008***
IL-6,pg/mL(2.2±1.8) 0.059±0.005*** 0.051±0.005*** 0.024+0.006***
Fibrinogen, mg/dL (323.8±67.3) 0.067±0.005** 0.063±0054*** 0032±0-006***
Internal carotid wall thickness, mm (1.5±0.7) 0.027±0.006*** 0.014±0.006 0.009±0.006
Each variable was examined for association with slL-2Ra in a separate model, adjusting for the variables listed in each model; the exception Is that 
a variable is not adjusted for Itself when it is being tested. β tor all measures except sex, race, diabetes mellitus, and hypertension are for a 1-SD 
change in the predictor. Model A: adjusted for age, race, and sex. Model B: adjusted for age, race, sex, smoking, diabetes mellitus, hypertension, 
systolic Mood pressure, and BMI. Model C: adjusted for age. race, sex, smoking, diabetes mellitus. hypertension, systolic blood pressure, BMI, 
LDL cholesterol, HDL cholesterol, C-reactive protein, IL-6, and fibrinogen. BMI indicates body mass index; CHS, Cardiovascular Health Study; 
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